Bridge Medicines Enters Exclusive License Agreement with Cornell University for UBR5 Inhibitor Program to Treat Resistant Cancers
Bridge Medicines Enters Exclusive License Agreement with Cornell University
Bridge Medicines Announces Additional Funding of $10 Million from Inside Investors
Bridge Medicines receives $10 million capital infusion from investors
Bridge Medicines Adds Small Molecule Inhibitors of Activated Factor XII to Pipeline
Bridge Medicines Signs Agreement with The Rockefeller University for
Bridge Medicines Enters Exclusive License Agreement with The Rockefeller University for Novel Epigenetic Leukemia Program
Epigenetic ENL-YEATS pathway shown to play a key role
Bridge Medicines Enters Agreement with Weill Cornell Medicine to Develop a Novel Sphingosine 1-Phosphate (S1P) Receptor Modulator
NEW YORK, NEW YORK – March 11, 2019 Bridge Medicines announced today an agreement with
Bridge Medicines Enters Agreement with Memorial Sloan Kettering to Develop Kidney‐Specific Delivery Platform for the Treatment of Acute Kidney Injury
NEW YORK, NEW YORK – July 23, 2018 Bridge Medicines announced today an agreement with Memorial
Bridge Medicines Appoints Louis M. Renzetti, Ph.D., As Chief Scientific Officer
NEW YORK, April 3, 2018 Bridge Medicines, a pioneering
Bridge Medicines Accepts Novel Small Molecule Targeting Basal Cell Carcinoma As First Drug Candidate for Development
Project Originated at Rockefeller University and Graduated From Tri-Institutional
Bridge Medicines Appoints William J. Polvino, M.D., As Chief Executive Officer
New York, NY – March 27, 2017 Bridge Medicines,
Pioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions through Human Proof of Concept
The Tri-Institutional Therapeutics Discovery Institute, a partnership between Memorial